Comparison of the Pharmacodynamic Effects of RanOlazine Versus aMlodipine on Platelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual ANtiplatelet Therapy - The ROMAN Randomized Study

Trial Profile

Comparison of the Pharmacodynamic Effects of RanOlazine Versus aMlodipine on Platelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual ANtiplatelet Therapy - The ROMAN Randomized Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Amlodipine (Primary) ; Ranolazine (Primary)
  • Indications Coronary artery disease
  • Focus Biomarker; Pharmacodynamics
  • Acronyms ROMAN
  • Most Recent Events

    • 06 Mar 2013 Actual initiation Date changed from 1 January 2012 to 1 January 2013 as reported by ClinicalTrials.gov.
    • 06 Mar 2013 Planned End Date changed from 1 Dec 2013 to 1 Dec 2018 as reported by ClinicalTrials.gov.
    • 01 Jan 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top